ARCHIVÉE - Évaluation sommative du programme de contributions pour la sûreté du sang

Annexe B : Publications examinées

• Agence française de sécurité sanitaire des produits de santé (AFSSAPS). (2005). Hémovigilance en France : rapport annuel (2004).
• Allain, J.P. (2003). Risques transfusionnels d'hier et d'aujourd'hui. Transfusion clinique et biologique, 10, 1-5.
• Amin, M., Wilson, K., Tinmouth, A. et Hébert, P. (2004). Does a perception of increased blood safety mean increased blood transfusion? An assessment of the risk compensation theory in Canada. BioMed Central Public Health, 4, 20.
• Andreu, G., Morel, P., Forestier, F, Debeir, J., Rebibo, D., Javier, G., & Hervé, P. (2002). Hemovigilance network in France: Organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion, 42, 1356-1364.
• AuBuchon, J.P., & Whitaker, B.I. (2007). America finds hemovigilance! Transfusion, 47, 1937-1942.
• Bihl, F., Castelli,D., Marincola, F., Dodd, R., & Brander, C. (2007). Transfusion-transmitted infections. Journal of Translational Medicine, 5, 1-11.
• Comité d'experts sur les maladies parasitaires à diffusion hématogène . (2002, septembre). Comité d'experts sur les maladies parasitaires à diffusion hématogène . Relevé des maladies transmissibles au Canada.
• Brinkerhoff, J. (2002). Assessing and improving partnership relationships and outcomes: A proposed framework. Evaluation and Program Planning, 25, 215-231.
• Buehler, J.W. (1998). Surveillance. In K.J. Rothman, & S. Greenland. Modern epidemiology (2nd ed.). Pennsylvania: Lippencott-Raven.
• Busch, M.P., Kleinman, S.H., & Nemo, G.J. (2003). Current and emerging infectious risks of blood transfusions. Journal of the American Medical Association, 289, 959-962.
• Conseil canadien pour le don et la transplantation (CCDT). Mohr, J. (2008). Surveillance of recipients of organ and tissue transplants.
• Centres for Disease Control and Prevention (CDC). (1999). An ounce of prevention: What are the returns? (2nd ed.). Georgia: Department of Health and Human Services, CDC.
• Centres for Disease Control and Prevention (CDC). (1999). Impact of vaccines universally recommended for children – United States, 1990–1998. Morbidity and Mortality Weekly Report, 48, 243-248.
• Commission Directive 2005/62/EC 30 Septembe 2005; implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. Journal officiel de l'Union européenne 2005, 1/10/2005, L 256/32-40.
• Centres for Disease Control and Prevention (CDC). (2001). Updated guidelines for evaluating public health surveillance systems: Recommendations from the guidelines working group. Morbidity and Mortality Weekly Report, 50, No. RR-13.
• Commission d'enquête sur l'approvisionnement en sang au Canada (1997). Rapport de la Commission Krever Extrait le 20 mai 2008, de www.phac-aspc.gc.ca/hcai-iamss/tti-it/goals-fra.php
• Commonwealth of Australia. (2004). Connection Government. Whole of Government Responses to Australia’s Priority Challenges, Good Practices Guides.
• Council of Europe Publishing. (2007). Guide to the preparation use and quality assurance of blood components: Recommendation No. R(95) 15 (13th ed.). Strasbourg, Cedex: Council of Europe.
• Davis, A., Mandal, R., Johnson, M., Makar, R., Stowell, C., & Dzik, S. (2008). A touch of TRALI. Transfusion, 48, 541-545.
• Directive 2002/98/EC of the European Parliament and of the Council. (2003). Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and produits sanguins and amending Directive 2001/83/EC. Journal officiel de l'Union européenne, 311, 67-128.
• Dodd, R.Y., Notari, E.P., & Stramer, S.L. (2002). Current prevalence and incidence of infectious disease markers and estimated windowperiod risk in the American Red Cross blood donor population. Transfusion, 42, 975-979.
• Engelfriet, C.P., & Reesink, H.W. (1999). Haemovigilance systems. Vox Sanguinis, 77, 110-120.
• Réseau européen d'hémovigilance. Extrait le 20 mai 2008, de http://www.ehn-org.net/
• Faber, J.C. (2000). L’hémovigilance en Europe. Transfusion clinique et biologique, 7, 5- 8.
• Faber, J.C. (2003). Hemovigilance: Definition and overview of current hemovigilance systems. Transfusion Alternatives in Transfusion Medicine, 5, 237-245.
• Faber, J.C. (2004). Worldwide overview of existing haemovigilance systems. Transfusion and Apheresis Science, 31, 99-110.
• Faber, J.C. (2006). European Haemovigilance Network: Organisation and Tasks. Transfusion Today, 66, 10-13.
• Gauvin, F., Lacroix, J., Robillard, P., Lapointe, H., & Hume, H. (2006). Acute transfusion reactions in the pediatric intensive care unit. Transfusion, 46, 1899-1908.
• Goldman, M., Webert, K.E., Arnold, D.M., Freedman, J., Hannon, J., & Blajchman, M.A. (2005). Proceedings of a concensus conference: Towards an understanding of TRALI. Transfusion Medicine Reviews, 19, 2-31.
• Gray, A., Jenkins, B., Leeuw, F., & Mayne, J. (2003). Collaboration in Public Services. Comparative Policy Analysis Volume X. New Brunswick (U.S.A.) and London (U.K.): Transaction Publishers.
• Comité de coordination de la surveillance médicale (CCSM), Direction générale de la santé de la population et de la santé publique et Santé Canada. (2004). Cadre d'évaluation des systèmes de surveillance de la santé (v 1.0).
• Heddell, G. (2007). Meeting the standards of the EU blood directive: Interview with Gerald Heddell by Barry Hill. The Biomedical Scientist, 12, 33: 29-32.
• Hinman, A.R., & Koplan, J.P. (1984). Pertussis and pertussis vaccine: Reanalysis of benefits, risks, and costs. Journal of the American Medical Association, 251, 3109–3113.
• Jorgensen, J., & Taaning, E. (2003). DART – A voluntary system of hemovigilance in Denmark. Transfusion Alternatives in Transfusion Medicine 5, 260-264.
• Krause, G. (2006). From evaluation to continuous quality assurance of surveillance systems. Eurosurveillance, 11, ii-657.
• Laperche, S. (2005). Blood safety and nucleic acid testing in Europe. Eurosurveillance, 10, 3-4.
• Le Drezen, L., Lepiouf, L., Léostic, C., Barra, J.A., & Le Niger, C. (2004). Démarche qualité en hémovigilance : analyse du processus transfusionnel. Transfusion clinique et biologique, 11, 138-145.
• Lozach, P., Vicariot., M., Le Niger, C., Pomey, M.P., Lejeune, B., Férec, C., Chaperon, J., & Salmi, L.R. (2001). Évaluation du système de notification des incidents transfusionnels immédiats au CHU de Brest. Transfusion clinique et biologique, 8, 343-349.
• Luban, N.L.C. (2005). Transfusion safety: Where are we today? Annals of the New York Academy of Sciences, 1054, 325-341.
• MacDonald, N. (2005). Transfusion and risk of infection in Canada: Update 2005. Journal canadien des maladies infectieuses et de la microbiologie médicale, 16, 161-165.
• McClelland, B., & Contreras, M. (2005). Appropriateness and safety of blood transfusion. British Medical Journal, 330, 104-105.
• National Health Surveillance Network Working Groups, (1999). Proposal to develop a network for health surveillance in Canada.
• New Zealand Ministry of Social Policy. (2000). Models of community government partnerships and their effectiveness in achieving welfare goals.
• Politis, C. (2005). The economics of blood. Transfusion Today, 65, 5-6.
• Agence de la santé publique du Canada. (2008). Surveillance de la maladie de Creutzfeldt-Jacob, extrait le 20 mai 20 2008, de http://www.phac-aspc.gc.ca/hcai-iamss/cjd-mcj/index-fra.php
• Rebibo, D, Hauser, L., Slimani, A., Herve, P., & Audreu, G. (2003). The French haemovigilance system: organization and results forK 2003. Transfusion and Apheresis Science, 31, 2, 145 -153.
• Robillard, E. (2006, septembre). The SITS Working Part of Haemovigilance. Transfusion Today, 68, 4.
• Robillard, E., Chan, P. and Kleinman, S. (2004). Hemovigilance for the improvement of blood safety. Transfusion and Apheresis Science, 31, 2, 95-98.
• Robillard, P., Nawej, K.I., & Jochem, K. (2004). The Quebec hemovigilance system: Description and results from the first two years. Transfusion and Apheresis Science, 31, 2, 111-122.
• Robinson, E. (2007). The European union blood safety directive and its implications for blood services. Vox Sanguinis, 93, 122-130.
• Rouger, P., & Hergon, E. (1998). Apport de l'hémovigilance à la sécurité immunologique des transfusions sanguines : bilan après 3 ans. Transfusion clinique et biologique, 5, 219-224.
• Serious Adverse Blood Reactions & Events (SABRE). Medicines and Healthcare Products Regulatory Agency (MHRA). (2005). SABRE – a user guide: UK blood safety and quality regulations 2005 – Implementation of the EU blood safety directive.
• Serious Hazards of Transfusion (SHOT). (2008, April). SHOT in 2008. SHOT 1(1). Extrait le 20 mai 2008, de www.shotuk.org/newsletter.pdf
• Serious Hazards of Transfusion (SHOT). Medicines and Healthcare Products Regulatory Agency (MHRA). (2005). UK blood safety and quality regulations 2005: Implementation of the EU blood safety directive – Background and guidance on reporting serious adverse events & serious adverse reactions.
• Stainsby, D., Jones, H., Asher, D., Atterbury, C., Boncinelli, A., Brant, L., Chapman, C.E., Davison, K., Gerrard, R., Gray, A., Knowles, S., Love, E.M., Milkins, C., Brian, D., McClelland L., Norfolk, D.R., Soldan, K., Taylor, C., Revill, J., Williamson, L.M., & Cohen, H. (2006). Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfusion Medicine Reviews, 20, 273-282.
• Stainsby, D., Jones, H., Wells, A.W., Gibson, B., & Cohen, H. (2008). Adverse outcomes of blood transfusion in children: analysis of UK reports to the serious hazards of transfusion scheme 1996-2005. British Journal of haematology, 141, 73-79.
• Stainsby, D, Williamson L, Jones H, & Cohen H. (2004). Transfusion and Apheresis Science, 31, 2, 95-98.
• Taylor-Powell, E. (1999). Evaluating Collaboratives: Challenges and Practice. The Evaluation Exchange Volume V, no. 2/3.
• Teutsch, S.M., & Thacker, S.B. (1995). Planning a public health surveillance system. Epidemiological Bulletin: Pan American Health Organization, 16, 1-6.
• Thacker, S.B. (2000). Historical development. In S.M. Teutsch, & R.E. Churchill (Ed.), Principles and practice of public health surveillance (2nd ed.). New York, NY: Oxford University Press.
• Thacker, S.B., & Berkelman, R.L. (1988). Public health surveillance in the United States. Epidemiologic Reviews, 10, 164-190.
• Secrétariat du Conseil du Trésor du Canada. (2007). Guide de préparation de la Partie III du Budget des dépenses : Rapports sur les plans et les priorités et Rapports ministériels sur le rendement. Secrétariat du Conseil du Trésor du Canada. (2008). Guide de préparation de la Partie III du Budget des dépenses : Tableau 16 – Initiatives horizontales.
• Turner, G. (2007). Creutzfeldt-Jakob disease: an update. The Biomedical Scientist, 6, 437-439.
• UK Blood Transfusion Services (2005), Guidelines for the Blood Transfusion Services in the United Kingdom. London, UK: CST.
• Vamvakas, E., Kleinman, S., Hume, H., & Sher, G. The development of West Nile virus safety policies by Canadian Blood Services: Guiding principles and a comparison between Canada and the United States. Transfusion Medicine Reviews, 20, 97-109.
• Van Hulst, M., De Wolf, J.T., Staginnus, U., Ruitenberg, E.J., & Postma, M.J. (2002). Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sanguinis, 83, 146-155.
• Verret, C., Mathoulin-Pélissier, Courbil, R., Perez, P., Destruel, F., Roubinet, F., Rech, H., Vidal, I., & Salmi, L.R. (1998). Evaluation of the system of traceability of the unstable produits sanguins in Midday-Pyrenees area. Transfusion clinique et biologique, 5, 275-282.
• Williamson, L.M. (2002). Transfusion hazard reporting: Powerful data, but do we know how best to use it? Transfusion, 42, 1249-1252.
• Wilson, K., & Hebert, P.C. (2003). The challenge of an increasingly expensive blood system. Journal de l'Association médicale canadienne, 168, 1149-1150.
• Organisation mondiale de la santé Genève. (2001). Making surveillance work. Module 4: Data management.